Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies
T Shih, C Lindley - Clinical therapeutics, 2006 - Elsevier
BACKGROUND:: Bevacizumab is a recombinant humanized monoclonal antibody that was
approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of
combination therapy with fluorouracil-based regimens for metastatic colorectal cancer
(mCRC). OBJECTIVES:: This article reviews the mechanism of action, clinical
pharmacology, and pharmacodynamic and pharmacokinetic properties of bevacizumab. It
summarizes data on the clinical efficacy and tolerability of bevacizumab from Phase II/III …
approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of
combination therapy with fluorouracil-based regimens for metastatic colorectal cancer
(mCRC). OBJECTIVES:: This article reviews the mechanism of action, clinical
pharmacology, and pharmacodynamic and pharmacokinetic properties of bevacizumab. It
summarizes data on the clinical efficacy and tolerability of bevacizumab from Phase II/III …